Read This Before Starting a GLP-1 Drug!

---

The new weight loss drugs are technically called "GLP-1 Agonists".  Over 10% of the US population are prescribed GLP-1 Agonists to combat obesity. (Kahn 2025).  According to the FAQs at one manufacturer's website, the GLP-1 Agonist “works by mimicking a hormone, called GLP-1 (glucagon-like peptide-1), which targets areas of the brain involved in regulating appetite and food intake. This can help you eat less, which can lead to weight loss.” What this means in plain English is that GLP-1 Agonists trick your brain into thinking that your body has produced GLP-1 hormones.  

The World Health Organization noted "the limited data on long-term efficacy and safety" of GLP-1 Agonists. (Celletti 2025).  Thus, we do not really have an extensive history to judge the long-term effects. (Moiz 2025). 

The number of people prescribed GLP-1 Agonists has allowed the study of large populations.  For example, a study of over 2 million people given various treatments found that patients taking GLP-1 drugs (as compared to other treatments) had modest reductions in poor mental health outcomes, substance use and psychotic disorders, and neurocognitive illnesses (e.g., Alzheimer and dementia), and seizures, and a lower risk of heart failure and stroke. (Xie, 2025) (Moiz 2025). 

By contrast, risks increased for gastrointestinal disorders, abnormally low blood pressure, loss of consciousness due to a drop in blood pressure, arthritic disorders, kidney stones, swollen kidney filters, and inflamed pancreas. (Xie 2025).  The most common gastrointestinal disorder side effects include nausea, vomiting, constipation, and diarrhea, which occur in up to 40% of people taking GLP-1 drugs. (Wharton 2022).  

Research also shows that Semaglutide alters how the tongue experiences taste and affects how the brain responds to taste, especially sweets. (Sever 2024).  Other research shows that GLP-1 Agonists decrease objective measures of taste, depress all 5 basic taste qualities, and have more side effects (e.g. nausea) for patients with better taste & smell. (Kahn 2025).

The World Health Organization commissioned a review of the studies by the healthcare non-profit The Cochrane Connection.  Published online, Cochrane found the following:

·  Tirzepatide (administered once weekly) resulted in approximately a 16% weight reduction after 12 to 18 months. Evidence from 8 randomized controlled trials (6,361 participants) also suggested these effects could be maintained for up to 3.5 years, although long-term safety data were limited.

·  Semaglutide (also injected weekly) reduced body weight by around 11% after 24 to 68 weeks, with effects likely sustained up to two years, drawing on 18 randomized controlled trials (27,949 participants). The drug increased the likelihood of achieving at least 5% body weight loss but was associated with higher rates of mild-to-moderate gastrointestinal side effects.

·  Liraglutide (a daily injection) resulted in a more modest average weight reduction of around 4–5%, based on 24 trials (9,937 participants), but still increased the proportion of people achieving meaningful weight loss compared with placebo. Evidence for longer-term effects beyond two years was more limited.

(Parkinson 2025).  Cochrane added that there was little to no difference between the drugs and a placebo for “major cardiovascular events, quality of life, or mortality. However, adverse events, particularly nausea and digestive symptoms, were more common among participants taking GLP-1 drugs, and some stopped treatment due to side effects.” (Id.). 

One unfortunate side effect of GLP-1 Agonists is muscle loss.  “[I]n some studies, reductions in lean mass range between 40% and 60% as a proportion of total weight lost, while other studies show lean mass reductions of approximately 15% or less of total weight lost.” (Neeland 2024).  

An important question is whether it is better to expel your own real GLP-1 hormones through The Progression Method™ eating and movement program, or to take a drug that merely makes you think that GLP-1 hormones are present in your system.  

No evidence exists that expelling your own GLP-1 hormones is harmful – GLP-1 hormones occur naturally in the body and are routinely expelled in varying amounts after eating. 

The truth is, we don’t really know how your body will react to a GLP-1 Agonist.  It might be great for you.  It might also be terrible.

Doesn’t it therefore make sense to first try The Progression Method™ program, and in the unlikely event that it does not work for you, then get a GLP-1 Agonist prescription?  

The Progression Method™ program does not cause the nausea or general malaise some taking GLP-1 Agonists experience.  In fact, it makes you feel great all day because you are not experiencing blood sugar spikes. 

The Progression Method™ program does not make your food taste terrible, as some people experience with GLP-1 Agonists.  In fact, it makes food taste better because the initial sequence of foods cleanses your palate so you can really taste your meal. 

The Progression Method™ program does not cause a loss of 15%-60% of your lean muscle mass.  In fact, if you sequence using protein, which is recommended, you may increase your lean muscle mass. (Wirth 2020).

The Progression Method™ program is virtually free.  The Progression Method™ book is priced so virtually anyone can afford it.  The foods recommended are almost certainly foods you already buy or have in your kitchen.  And the post-meal movement requires no special equipment or membership.  

Before taking an expensive drug with unknown long-term effects, buy the Progression Method™ book only on Amazon.